Lotus Pharmaceutical Co (美時製藥) yesterday said it has signed an exclusive marketing agreement with Finland-based Orion Oyj for the distribution of its drugs to treat Parkinson’s disease in select Asian markets.
Lotus is to help Orion sell and distribute its branded drug Stalevo in Taiwan, Bangladesh, Hong Kong, Indonesia, the Philippines, South Korea and Vietnam, it said in a statement.
The company is also to sell Orion’s Comtan, another drug used to treat Parkinson’s disease, in Taiwan, Hong Kong, the Philippines and South Korea, it added.
Novartis Pharma AG currently holds the rights to sell and distribute the two proprietary drugs in those markets.
Those rights are to be transferred to Lotus in the third quarter of next year, the firm said.
“Novartis marketed Stalevo as a second-line treatment for Parkinson’s disease in those countries, which are recommended by doctors when the first-line therapy does not work,” Lotus acting spokeswoman Nadiya Chen (陳荻雅) told the Taipei Times by telephone.
“However, Orion expects the drug to be used as a first-line treatment. That was the main reason why the Finnish company looked to change its marketing partner and sought our help,” Chen said.
Stalevo, which contains active pharmaceutical ingredients including levodopa, carbidopa and entacapone, has been used as a first-line drug in several overseas markets after Orion marketed the drug itself following its acquisition of the sales rights from Novartis last year, she added.
According to the agreement signed by Orion and Lotus, Orion would be responsible for manufacturing the products and the agreement would be in effect for five years following the first commercial sales.
Lotus expects sales of Stalevo to boost its revenue in the next few years, given the huge market for Parkinson’s treatment, Chen said.
The market was approximately US$1.04 billion across Asia last year and is estimated to increase at a compound annual growth rate of 6.8 percent, reaching US$1.44 billion by 2023, according to research firm Market Data Forecast, she said.
“Despite the heavy competition in Parkinson’s disease treatment, with many generic drugs in the market, we are confident about Stalevo and Comtan, as they are among the most frequently prescribed drugs,” Chen said.
Lotus sees Roche’s Madopar as Stalevo’s biggest rival in those Asian markets, but is not concerned about competition from generic drugs as many doctors and patients prefer branded drugs, she said.
While this is the first cooperation agreement between Lotus and Orion, the Taiwanese firm has partnerships with other companies to market their branded drugs, including Aclasta and Evista, which are used to treat osteoporosis, and Mercilon, a combined contraceptive pill.
The demise of the coal industry left the US’ Appalachian region in tatters, with lost jobs, spoiled water and countless kilometers of abandoned underground mines. Now entrepreneurs are eyeing the rural region with ambitious visions to rebuild its economy by converting old mines into solar power systems and data centers that could help fuel the increasing power demands of the artificial intelligence (AI) boom. One such project is underway by a non-profit team calling itself Energy DELTA (Discovery, Education, Learning and Technology Accelerator) Lab, which is looking to develop energy sources on about 26,305 hectares of old coal land in
Taiwan’s exports soared 56 percent year-on-year to an all-time high of US$64.05 billion last month, propelled by surging global demand for artificial intelligence (AI), high-performance computing and cloud service infrastructure, the Ministry of Finance said yesterday. Department of Statistics Director-General Beatrice Tsai (蔡美娜) called the figure an unexpected upside surprise, citing a wave of technology orders from overseas customers alongside the usual year-end shopping season for technology products. Growth is likely to remain strong this month, she said, projecting a 40 percent to 45 percent expansion on an annual basis. The outperformance could prompt the Directorate-General of Budget, Accounting and
Netflix on Friday faced fierce criticism over its blockbuster deal to acquire Warner Bros Discovery. The streaming giant is already viewed as a pariah in some Hollywood circles, largely due to its reluctance to release content in theaters and its disruption of traditional industry practices. As Netflix emerged as the likely winning bidder for Warner Bros — the studio behind Casablanca, the Harry Potter movies and Friends — Hollywood’s elite launched an aggressive campaign against the acquisition. Titanic director James Cameron called the buyout a “disaster,” while a group of prominent producers are lobbying US Congress to oppose the deal,
Two Chinese chipmakers are attracting strong retail investor demand, buoyed by industry peer Moore Threads Technology Co’s (摩爾線程) stellar debut. The retail portion of MetaX Integrated Circuits (Shanghai) Co’s (上海沐曦) upcoming initial public offering (IPO) was 2,986 times oversubscribed on Friday, according to a filing. Meanwhile, Beijing Onmicro Electronics Co (北京昂瑞微), which makes radio frequency chips, was 2,899 times oversubscribed on Friday, its filing showed. The bids coincided with Moore Threads’ trading debut, which surged 425 percent on Friday after raising 8 billion yuan (US$1.13 billion) on bets that the company could emerge as a viable local competitor to Nvidia
RSS